Literature DB >> 31110048

Target sequence requirements of a type III-B CRISPR-Cas immune system.

Kaitlin Johnson1, Brian A Learn1, Michael A Estrella1, Scott Bailey2,3.   

Abstract

CRISPR-Cas systems are RNA-based immune systems that protect many prokaryotes from invasion by viruses and plasmids. Type III CRISPR systems are unique, as their targeting mechanism requires target transcription. Upon transcript binding, DNA cleavage by type III effector complexes is activated. Type III systems must differentiate between invader and native transcripts to prevent autoimmunity. Transcript origin is dictated by the sequence that flanks the 3' end of the RNA target site (called the PFS). However, how the PFS is recognized may vary among different type III systems. Here, using purified proteins and in vitro assays, we define how the type III-B effector from the hyperthermophilic bacterium Thermotoga maritima discriminates between native and invader transcripts. We show that native transcripts are recognized by base pairing at positions -2 to -5 of the PFS and by a guanine at position -1, which is not recognized by base pairing. We also show that mismatches with the RNA target are highly tolerated in this system, except for those nucleotides adjacent to the PFS. These findings define the target requirement for the type III-B system from T. maritima and provide a framework for understanding the target requirements of type III systems as a whole.
© 2019 Johnson et al.

Entities:  

Keywords:  CRISPR-Cas; CRISPR-RNA; Cmr effector complex; DNA; RNA; bacterial immunity; crRNA; deoxyribonuclease (DNase); nucleotide mismatch; ribonuclease; sequence similarity

Mesh:

Substances:

Year:  2019        PMID: 31110048      PMCID: PMC6664175          DOI: 10.1074/jbc.RA119.008728

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  Mature clustered, regularly interspaced, short palindromic repeats RNA (crRNA) length is measured by a ruler mechanism anchored at the precursor processing site.

Authors:  Asma Hatoum-Aslan; Inbal Maniv; Luciano A Marraffini
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

2.  Type III-A CRISPR-Cas Csm Complexes: Assembly, Periodic RNA Cleavage, DNase Activity Regulation, and Autoimmunity.

Authors:  Ning Jia; Charlie Y Mo; Chongyuan Wang; Edward T Eng; Luciano A Marraffini; Dinshaw J Patel
Journal:  Mol Cell       Date:  2018-11-29       Impact factor: 17.970

3.  CRISPR provides acquired resistance against viruses in prokaryotes.

Authors:  Rodolphe Barrangou; Christophe Fremaux; Hélène Deveau; Melissa Richards; Patrick Boyaval; Sylvain Moineau; Dennis A Romero; Philippe Horvath
Journal:  Science       Date:  2007-03-23       Impact factor: 47.728

4.  RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions.

Authors:  Blake Wiedenheft; Esther van Duijn; Jelle B Bultema; Jelle Bultema; Sakharam P Waghmare; Sakharam Waghmare; Kaihong Zhou; Arjan Barendregt; Wiebke Westphal; Albert J R Heck; Albert Heck; Egbert J Boekema; Egbert Boekema; Mark J Dickman; Mark Dickman; Jennifer A Doudna
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-02       Impact factor: 11.205

5.  A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems.

Authors:  Migle Kazlauskiene; Georgij Kostiuk; Česlovas Venclovas; Gintautas Tamulaitis; Virginijus Siksnys
Journal:  Science       Date:  2017-06-29       Impact factor: 47.728

6.  Impact of Different Target Sequences on Type III CRISPR-Cas Immunity.

Authors:  Inbal Maniv; Wenyan Jiang; David Bikard; Luciano A Marraffini
Journal:  J Bacteriol       Date:  2016-01-11       Impact factor: 3.490

7.  Broad Targeting Specificity during Bacterial Type III CRISPR-Cas Immunity Constrains Viral Escape.

Authors:  Nora C Pyenson; Kaitlyn Gayvert; Andrew Varble; Olivier Elemento; Luciano A Marraffini
Journal:  Cell Host Microbe       Date:  2017-08-17       Impact factor: 21.023

8.  RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex.

Authors:  Caryn R Hale; Peng Zhao; Sara Olson; Michael O Duff; Brenton R Graveley; Lance Wells; Rebecca M Terns; Michael P Terns
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

9.  Structural biology. Structures of the CRISPR-Cmr complex reveal mode of RNA target positioning.

Authors:  David W Taylor; Yifan Zhu; Raymond H J Staals; Jack E Kornfeld; Akeo Shinkai; John van der Oost; Eva Nogales; Jennifer A Doudna
Journal:  Science       Date:  2015-04-02       Impact factor: 47.728

10.  Structure and mechanism of the CMR complex for CRISPR-mediated antiviral immunity.

Authors:  Jing Zhang; Christophe Rouillon; Melina Kerou; Judith Reeks; Kim Brugger; Shirley Graham; Julia Reimann; Giuseppe Cannone; Huanting Liu; Sonja-Verena Albers; James H Naismith; Laura Spagnolo; Malcolm F White
Journal:  Mol Cell       Date:  2012-01-05       Impact factor: 17.970

View more
  11 in total

Review 1.  CRISPR Tools To Control Gene Expression in Bacteria.

Authors:  Antoine Vigouroux; David Bikard
Journal:  Microbiol Mol Biol Rev       Date:  2020-04-01       Impact factor: 11.056

Review 2.  Chemistry of Class 1 CRISPR-Cas effectors: Binding, editing, and regulation.

Authors:  Tina Y Liu; Jennifer A Doudna
Journal:  J Biol Chem       Date:  2020-08-14       Impact factor: 5.157

Review 3.  RNA-targeting CRISPR-Cas systems.

Authors:  Sam P B van Beljouw; Jasper Sanders; Alicia Rodríguez-Molina; Stan J J Brouns
Journal:  Nat Rev Microbiol       Date:  2022-09-28       Impact factor: 78.297

4.  Reprogramming CRISPR-Mediated RNA Interference for Silencing of Essential Genes in Sulfolobales.

Authors:  Erika Wimmer; Isabelle Anna Zink; Christa Schleper
Journal:  Methods Mol Biol       Date:  2022

5.  Type III CRISPR-based RNA editing for programmable control of SARS-CoV-2 and human coronaviruses.

Authors:  Ping Lin; Guanwang Shen; Kai Guo; Shugang Qin; Qinqin Pu; Zhihan Wang; Pan Gao; Zhenwei Xia; Nadeem Khan; Jianxin Jiang; Qingyou Xia; Min Wu
Journal:  Nucleic Acids Res       Date:  2022-05-06       Impact factor: 19.160

6.  Cyclic oligoadenylate signalling mediates Mycobacterium tuberculosis CRISPR defence.

Authors:  Sabine Grüschow; Januka S Athukoralage; Shirley Graham; Tess Hoogeboom; Malcolm F White
Journal:  Nucleic Acids Res       Date:  2019-09-26       Impact factor: 16.971

Review 7.  The Cyclic Oligoadenylate Signaling Pathway of Type III CRISPR-Cas Systems.

Authors:  Fengtao Huang; Bin Zhu
Journal:  Front Microbiol       Date:  2021-01-20       Impact factor: 5.640

8.  Regulation of the RNA and DNA nuclease activities required for Pyrococcus furiosus Type III-B CRISPR-Cas immunity.

Authors:  Kawanda Foster; Sabine Grüschow; Scott Bailey; Malcolm F White; Michael P Terns
Journal:  Nucleic Acids Res       Date:  2020-05-07       Impact factor: 16.971

9.  The dynamic interplay of host and viral enzymes in type III CRISPR-mediated cyclic nucleotide signalling.

Authors:  Januka S Athukoralage; Shirley Graham; Christophe Rouillon; Sabine Grüschow; Clarissa M Czekster; Malcolm F White
Journal:  Elife       Date:  2020-04-27       Impact factor: 8.140

10.  Specificity and sensitivity of an RNA targeting type III CRISPR complex coupled with a NucC endonuclease effector.

Authors:  Sabine Grüschow; Catherine S Adamson; Malcolm F White
Journal:  Nucleic Acids Res       Date:  2021-12-16       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.